Oruka Therapeutics price target raised to $85 from $45 at Wedbush [Yahoo! Finance]
Oruka Therapeutics, Inc. (ORKA)
Company Research
Source: Yahoo! Finance
The firm reviewed anticipated benchmarks and stock setup for upcoming induction data from the Phase 2a EVERLAST-A trial of ORKA-001 for psoriasis. Wedbush speculates a data readout is likely in May, and models a valuation of $4.77B for ORKA-001 in a base case scenario with PASI-100 rates of 35%-40%, consistent with other IL-23 mAbs in psoriasis. Further, the firm anticipates tiered upside scenarios with PASI-100 efficacy thresholds of 40%-50%, 50%-60%, and over 60% yielding respective valuations of $5.56B, $6.35B, and $14.2B based on expected market share increases and progressively accelerated trial timelines. Oruka remains one of Wedbush's top picks for 2026 and the firm sees room for sustained growth even from current levels. Claim 30% Off TipRanks Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Published first on TheFly – the u
Show less
Read more
Impact Snapshot
Event Time:
ORKA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORKA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORKA alerts
High impacting Oruka Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ORKA
News
- Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors [Yahoo! Finance]Yahoo! Finance
- Oruka Therapeutics (ORKA) had its price target raised by Wedbush from $45.00 to $85.00. They now have an "outperform" rating on the stock.MarketBeat
- Oruka Therapeutics (ORKA) had its "buy" rating reaffirmed by Guggenheim. They now have a $125.00 price target on the stock.MarketBeat
- Oruka Therapeutics (ORKA) had its price target raised by BTIG Research from $73.00 to $78.00. They now have a "buy" rating on the stock.MarketBeat
ORKA
Earnings
- 3/12/26 - Beat
ORKA
Sec Filings
- 4/21/26 - Form 424B7
- 4/17/26 - Form ARS
- 4/17/26 - Form DEFA14A
- ORKA's page on the SEC website